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PMH9
ANALYSIS OF ANTIDEPRESSANT MEDICATION UTILIZATION
AND ADHERENCE OF MANAGED CARE PATIENTS ENROLLED
IN A MEDICATION ADHERENCE PROGRAM
Cockerham TR1,Ara SB2,Waugh WJ1
1WellPoint Pharmacy Management, West Hills, CA, USA; 2Health Net,
Woodland Hills, CA, USA
OBJECTIVE: To examine antidepressant medication utilization
and adherence of managed care patients enrolled in a medica-
tion adherence program. METHODS: This was an aggregate,
retrospective cohort analysis of pharmacy and eligibility claims
databases from four health plans. The study cohorts included
antidepressant new starts (no antidepressant in the previous 4
months) 18 years or older between September 1, 2001 and July
31, 2002 who were continuously enrolled during the study
period and were nonadherent with therapy. The nonadherent cri-
teria for 3 plans was >10 days late in ﬁlling medication and was
>20 days late for 1 plan. The intervention cohort consisted of
patients enrolled in the program whose physicians were notiﬁed
of nonadherence in ﬁlling antidepressant medications. The
control cohort included nonadherent patients not enrolled in the
program. A t-test was used to evaluate differences in medication
utilization. A multivariate linear regression analysis was per-
formed to estimate the association of the intervention with 
medication adherence (deﬁned as medication possession ratio
[MPR]) when adjusted for relevant covariates. RESULTS: The
control (N = 13,152) and intervention (N = 2296) cohorts were
comparable in age and gender; however, the control had a higher
mean copay per patient per prescription ($16.93 vs. $12.33; p <
0.0001). Six-month evaluation of antidepressant pharmacy
claims showed the intervened patients had a higher average
number of prescriptions (4.5 vs. 4.1), quantity dispensed (213
vs. 164) and days coverage (140 vs. 124); p < 0.0001. The inter-
vention cohort lowered the mean number of gap days between
medication ﬁlls (32 vs. 54; p < 0.0001) and improved mean MPR
(81% vs. 67%; p < 0.0001). Multivariate analysis demonstrated
MPR was associated with enrollment in the program (p <
0.0001), copay (p = 0.0131), therapy initiation with selective
serotonin inhibitors (p < 0.0001) and > 20 day nonadherent cri-
teria (p < 0.0001). CONCLUSIONS: Antidepressant medication
utilization and adherence can improve with physician notiﬁca-
tion of nonadherent patients. The nonadherent criteria of > 20
days negatively impacted the aggregate MPR.
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PEDIATRIC ANTIDEPRESSANT PRESCRIPTION 
PATTERNS
Cossrow N,Von Allmen H, Henderson SC, Luce J,Yoder S,
Morris LS
IMS Health, Plymouth Meeting, PA, USA
OBJECTIVE: Prevalence of Major Depressive Disorder (MDD)
ranges from 3% to 8% in children and adolescents. Numerous
antidepressants exist, but only ﬂuoxetine is indicated for pedi-
atric MDD. Recent federal acts require pharmaceutical compa-
nies to evaluate efﬁcacy and safety of products in pediatric
populations. However, to most effectively treat their pediatric
patients, physicians will use the best available resources even if
it means prescribing antidepressants off-label. In light of recent
warnings and concerns regarding antidepressants in pediatric
populations, the purpose of this study is to examine use of anti-
depressants, prescriber specialties prescribing antidepressants
and persistency of antidepressants in children and adolescents.
METHODS: Using a geographically diverse and representative
prescription database, patients between 5 and 17 years of age
who ﬁlled a ﬁrst prescription for an antidepressant between July
21, 2001 and April 19, 2002 were identiﬁed and grouped as chil-
dren (5–11 years) or adolescents (12–17 years). Antidepressants
were categorized by drug class: tricyclic antidepressants (TCA),
selective serotonin reuptake inhibitors or serotonin-norepineph-
rine reuptake inhibitor (SSRI/SNRI) and newer generation anti-
depressants (NGAD). Prescribers were categorized by specialty:
psychiatrists, pediatricians, primary care physicians (PCPs), and
other. RESULTS: There were 100,280 children (64.1 % males)
and 237,236 adolescents (45.3% males). Among children and
adolescents, 54.5% and 67.3%, respectively, of new product
starts were for an SSRI/SNRI; only 21.4% and 23.3%, respec-
tively, started on ﬂuoxetine. For children and adolescents, psy-
chiatrists were least likely to prescribe a TCA. Psychiatrists 
and pediatricians were most likely to prescribe SSRI/SNRIs to
children; PCPs and pediatricians were most likely to prescribe
SSRI/SNRIs to adolescents. For children and adolescents, persis-
tency was longest for SSRI/SNRIs. CONCLUSIONS: These
results indicate that in pediatric populations there is either con-
siderable off-label use of anti-depressants or that these products
are used for indications other than MDD. These results have risk
management implications and may facilitate further investiga-
tion of pediatric antidepressant use.
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ANTIDEPRESSANT USE AND RISK OF SUICIDE ATTEMPT IN
ADOLESCENTS WITH MAJOR DEPRESSIVE DISORDER
Valuck RJ1, Libby AM1, Sills MR1,Allen RR2, Giese AA1
1University of Colorado Health Sciences Center, Denver, CO, USA;
2Peak Statistical Services, Inc, Denver, CO, USA
OBJECTIVE: To investigate a hypothesized link between anti-
depressant (AD) drug use in pediatric patients with major depres-
sive disorder (MDD) and an increased rate of suicide attempts.
METHODS: A retrospective cohort study was conducted using
claims data from the PharMetrics Integrated Outcomes Database
from 1997–2002. Adolescents (aged 12–18 at time of MDD
diagnosis) who were continuously enrolled in a managed health
plan; had no prior diagnosis of MDD, AD use, or psychother-
apy for one year; and had at least 6 months of follow-up data
were included. Cox Proportional Hazard models were created to
evaluate the multivariate relationship between AD use and time
to suicide attempt, controlling for calendar year, demographic
and clinical characteristics, and patient compliance. AD use was
measured using pharmacy claims; suicide attempts were mea-
sured using ICD-9 codes in any health care setting. RESULTS:
A total of 15,826 subjects (63% of whom were female) met
inclusion criteria. AD treatment with any class of drugs did not
increase the risk of suicide attempt (all Hazard Ratios NS). No
statistically signiﬁcant differences were found between more- and
less-activating agents. AD treatment for less than 6 months was
associated with increased risk of suicide attempt: subjects taking
AD for 1–55 days (HR = 2.93, 95% CI = 1.34–6.39) or 56–179
days (HR = 3.26, 95% CI = 1.81–5.87) were more likely than
subjects taking AD for 180 days or more to attempt suicide. Ado-
lescent females, those receiving psychotherapy within 90 days of
MDD diagnosis, those with diagnosed substance abuse, schizo-
phrenia, or another mental health disorder, those with more
chronic diseases, and those in the Midwest and West were inde-
pendently at greater risk for suicide attempts. CONCLUSIONS:
Antidepressant drug use had no independent effect on the like-
lihood of suicide attempt for a large cohort of adolescents across
the U.S. The relationship between AD drug use and suicidality
is complex and requires further investigation.
